Janssen, “We’ll start Phase II clinical trial of new obesity & diabetes biologic”
The global Phase II clinical trial for HM12525A, a Hanmi Pharm’s new obesity & diabetes biologic being developed by Janssen, a global pharmaceutical company, will start soon. The clinical trial will evaluate efficacy of ‘HM12525A’ on 440 severe obesity patients.
ClinicalTrials.gov, a U.S. clinic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
